[1]林飞帆,石学军,王春光.替吉奥对比卡培他滨在晚期乳腺癌疗效及安全性的Meta分析[J].医学信息,2019,32(10):91-94.[doi:10.3969/j.issn.1006-1959.2019.10.029]
　LIN Fei-fan,SHI Xue-jun,WANG Chun-guang.Meta-analysis of the Efficacy and Safety of Tiggio Versus Capecitabine in Advanced Breast Cancer[J].Journal of Medical Information,2019,32(10):91-94.[doi:10.3969/j.issn.1006-1959.2019.10.029]
点击复制

替吉奥对比卡培他滨在晚期乳腺癌疗效及安全性的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年10期
页码:
91-94
栏目:
论著
出版日期:
2019-05-15

文章信息/Info

Title:
Meta-analysis of the Efficacy and Safety of Tiggio Versus Capecitabine in Advanced Breast Cancer
文章编号:
1006-1959（2019）10-0091-04
作者:
林飞帆; 石学军; 王春光
（重庆医科大学附属永川医院肿瘤内科，重庆 402160）
Author(s):
LIN Fei-fan; SHI Xue-jun; WANG Chun-guang
(Department of Oncology,Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing 402160,China)
关键词:
替吉奥; 卡培他; 晚期乳腺癌; Meta分析
Keywords:
Tiggio; Capecita; Advanced breast cancer; Meta-analysis
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2019.10.029
文献标志码:
A
摘要:
目的 对替吉奥与卡培他滨在晚期乳腺癌的疗效及安全性进行Meta分析。方法 计算机检索Pubmed、The Cochrane Library、EMbase、CKNI、万方数据库，按照纳入和排除标准筛选文献和提取资料后，采用 RevMan 5.3 软件进行Meta分析。结果 最终纳入12篇文献，包括829例患者。Meta分析结果显示，替吉奥较卡培他滨能有效改善晚期乳腺癌疾病控制率，差异有统计学意义[OR=1.64（1.12，2.40），P=0.01]；而二者客观缓解率比较，差异无统计学意义[OR=1.34（0.99，1.81），P=0.05]；安全性方面：替吉奥在恶性呕吐[OR=0.32（0.16，0.65），P=0.002]、手足综合症[OR=0.14（0.06，0.30），P＜0.00001]发生率低于卡培他滨，差异有统计学意义。结论 在治疗晚期乳腺癌方面，替吉奥与卡培他滨相比能有效改善疾病控制率，在恶性呕吐及手足综合症方面具有更良好的安全性。
Abstract:
Objective To conduct a meta-analysis of the efficacy and safety of Tiggio and capecitabine in advanced breast cancer. Methods The Pubmed, The Cochrane Library, EMbase, CKNI, and Wanfang databases were searched by computer. After screening and extracting data according to inclusion and exclusion criteria, meta-analysis was performed using RevMan 5.3 software. Results A total of 12 articles were included, including 829 patients. Meta-analysis showed that Tiggio was more effective than capecitabine in improving the control rate of advanced breast cancer, and the difference was statistically significant [OR=1.64 (1.12, 2.40), P=0.01]; The difference was not statistically significant [OR=1.34 (0.99, 1.81), P=0.05]; safety: Tiggio in malignant vomiting [OR=0.32 (0.16, 0.65), P=0.002], hand-foot syndrome [ The incidence of OR=0.14 (0.06, 0.30), P<0.00001] was lower than that of capecitabine, and the difference was statistically significant. Conclusion In the treatment of advanced breast cancer, tiggio can effectively improve the disease control rate compared with capecitabine, and has better safety in malignant vomiting and hand-foot syndrome.

参考文献/References:

[1]Redig AJ,McAllister SS.Breast cancer as a systemic disease:a view of metastasis[J].J Intern Med,2013,274(2):113-126.
[2]DeSantis C,Ma J,Bryan L,et al.Breast cancer statistics,2013[J].CA Cancer J Clin,2014,64(1):52-62.
[3]Russell CA.Personalized medicine for breast cancer:it is a new day[J].Am J Surg,2014,207(3):321-325.
[4]Fan L,Strasser-Weippl K,Li JJ,et al.Breast cancer in China[J].Lancet Oncol,2014,15(7):e279-e289.
[5]Gradishar WJ,Anderson BO,Balassanian R,et al.NCCN Guidelines Insights: Breast Cancer,Version 1.2017[J].J Natl Compr Canc Netw,2017,15(4):433-451.
[6]Lee JL,Kang YK,Kang HJ,et al.A randomised multicentre phaseⅡ trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J].Br J Cancer,2008,99(4):584-590.
[7]Abdel-Rahman O,ElHalawani H,Essam-Eldin S.S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines[J]. Expert Opin Drug Saf,2016,15(1):5-20.
[8]焦洋,宁洁,王芳,等.晚期乳腺癌替吉奥与卡培他滨治疗疗效及安全性对比研究[J].中华肿瘤防治杂志,2016,23(7):452-456.
[9]肖妤,胡纲.研究卡培他滨和替吉奥单药治疗老年晚期乳腺癌的临床疗效及安全性比较[J].世界最新医学信息文摘,2016,16(30):16-17.
[10]张维平.替吉奥和卡培他滨治疗老年晚期乳腺癌的可行性研究[J].海峡药学,2015,27(7):165-166.
[11]吴昱冶.替吉奥和卡培他滨治疗老年晚期乳腺癌的可行性及安全性[J].现代诊断与治疗,2015,26(6):1279-1280.
[12]王梦洁,孙苏平.替吉奥和卡培他滨治疗老年晚期乳腺癌临床疗效及安全性比较[J].现代仪器与医疗,2014,20(6):36-38.
[13]翟洪梅.替吉奥联合多西他赛治疗转移性乳腺癌的临床疗效[J].中国药物经济学,2014,9(10):211-213.
[14]陈泰华,陈科平.替吉奥胶囊治疗蒽环类和紫杉醇化疗失败后乳腺癌的临床分析[J].现代中西医结合杂志,2013,22(35):3956-3957.
[15]肖宏卫,吴灿,李远东,等.替吉奥与希罗达分别联合多西他赛治疗转移性乳腺癌的随机对照研究[J].现代肿瘤医学,2013, 21(8):1753-1756.
[16]代醒,李向柯,吴海波,等.替吉奥单药治疗老年晚期乳腺癌的临床疗效与安全性[J].肿瘤防治研究,2013,40(5):481-484.
[17]李杰,王先国,张学伟.替吉奥与卡培他滨分别联合多西紫杉醇治疗晚期乳腺癌的临床观察[J].中国癌症防治杂志,2012, 4(4):343-346.
[18]曾守群,陈远航,何平,等.替吉奥联合多西他赛治疗复发转移性乳腺癌的疗效观察[J].山东医药,2012,52(37):84-85.
[19]Yamamoto D,Iwase S,Tsubota Y,et al.A Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer:Japan Breast Cancer Research Network 05 Trial[J].Cancer Chemother Pharmacol,2015,75(6):1183-1189.
[20]Tahara M,Kiyota N,Mizusawa J,et al.PhaseⅡ trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer(JCOG0706)[J].Cancer Sci,2015,106(6):726-733.
[21]Abdel-Rahman O,ElHalawani H.S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer:a meta-analysis[J].Future Oncol,2016,12(5):701-713.
[22]He AB,Peng XL,Song J,et al.Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis[J].World J Gastroenterol,2015,21(14):4358-4364.
[23]Yamamoto D,Iwase S,Yoshida H,et al.Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network(JBCRN)04-1 trial[J].Anticancer Res,2010,30(9):3827-3831.

相似文献/References:

[1]李 光.替吉奥联合阿帕替尼治疗晚期胰腺癌的疗效分析[J].医学信息,2018,31(16):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
　LI Guang.Therapeutic Effect of Tiggio Combined with Apatinib in the Treatment of Advanced Pancreatic Cancer[J].Journal of Medical Information,2018,31(10):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
[2]张晓玲.替吉奥联合多西他赛治疗转移性乳腺癌的临床疗效观察[J].医学信息,2018,31(20):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
　ZHANG Xiao-ling.Clinical Observation of Tegafur,Gimeracil and Oteracil Porassium Capsules Combined with Docetaxel in the Treatment of Metastatic Breast Cancer[J].Journal of Medical Information,2018,31(10):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
[3]王逸飞,王 志,左宏波,等.伊利替康联合替吉奥在晚期结直肠癌治疗的临床研究[J].医学信息,2019,32(07):158.[doi:10.3969/j.issn.1006-1959.2019.07.049]
　WANG Yi-fei,WANG Zhi,ZUO Hong-bo,et al.Clinical Study of Irinotecan Combined with Tegafur,Gimeracil and Oteracil Porassium Capsulesin the Treatment of Advanced Colorectal Cancer[J].Journal of Medical Information,2019,32(10):158.[doi:10.3969/j.issn.1006-1959.2019.07.049]
[4]郭 雪,石学军.替吉奥与卡培他滨同步放疗治疗复发性结直肠癌疗效与安全性的Meta分析[J].医学信息,2020,33(07):71.[doi:10.3969/j.issn.1006-1959.2020.07.021]
　GUO Xue,SHI Xue-jun.Meta-analysis of the Efficacy and Safety of Simultaneous Therapy of Tegafur and Capecitabine for Recurrent Colorectal Cancer[J].Journal of Medical Information,2020,33(10):71.[doi:10.3969/j.issn.1006-1959.2020.07.021]
[5]杨 欢,朱 梅,张改琴,等.多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果[J].医学信息,2022,35(19):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]
　YANG Huan,ZHU Mei,ZHANG Gai-qin,et al.Effect of Docetaxel Intraperitoneal Perfusion Plus Intravenous Chemotherapy and Oral Tegafur Combined with Apatinib in the Treatment of Gastric Cancer Patients with Peritoneal Metastasis[J].Journal of Medical Information,2022,35(10):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]
[6]谢兴江,彭 强,侯松林,等.SOX和XELOX在进展期胃癌新辅助化疗中疗效及不良反应差异的Meta分析[J].医学信息,2021,34(07):67.[doi:10.3969/j.issn.1006-1959.2021.07.019]
　XIE Xing-jiang,PENG Qiang,HOU Song-lin,et al.Meta-analysis of the Differences in the Efficacy and Adverse Reactions of SOX and XELOX in Neoadjuvant Chemotherapy for Advanced Gastric Cancer[J].Journal of Medical Information,2021,34(10):67.[doi:10.3969/j.issn.1006-1959.2021.07.019]

更新日期/Last Update: 2019-05-15